Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 18;9(5):768-79.
doi: 10.18240/ijo.2016.05.24. eCollection 2016.

Molecular underpinnings of corneal angiogenesis: advances over the past decade

Nizar Saleh Abdelfattah  1 , Mohamed Amgad  2 , Amira A Zayed  3 , Heba Hussein  4 , Nawal Abd El-Baky  5
Affiliations
Review

Molecular underpinnings of corneal angiogenesis: advances over the past decade

Nizar Saleh Abdelfattah et al. Int J Ophthalmol. .

Abstract

The cornea is maintained in an avascular state by maintaining an environment whereby anti-angiogenic factors take the upper hand over factors promoting angiogenesis. Many of the common pathologies affecting the cornea involve the disruption of such equilibrium and the shift towards new vessel formation, leading to corneal opacity and eventually-vision loss. Therefore it is of paramount importance that the molecular underpinnings of corneal neovascularization (CNV) be clearly understood, in order to develop better targeted treatments. This article is a review of the literature on the recent discoveries regarding pro-angiogenic factors of the cornea (such as vascular endothelial growth factors, fibroblast growth factor and matrix metalloproteinases) and anti-angiogenic factors of the cornea (such as endostatins and neostatins). Further, we review the molecular underpinnings of lymphangiogenesis, a process now known to be almost separate from (yet related to) hemangiogenesis.

Keywords: angiogenesis; cornea; lymphangiogenesis; neovascularization; vascular endothelial growth factor.

PubMed Disclaimer

References

    1. Abdelfattah NS, Amgad M, Salama AA, Israel ME, Elhawary GA, Radwan AE, Elgayar MM, El Nakhal TM, Elkhateb IT, Hashem HA, Embaby DK, Elabd AA, Elwy RK, Yacoub MS, Salem H, Abdel-Baqy M, Kassem A. Development of an Arabic version of the National Eye Institute Visual Function Questionnaire as a tool to study eye diseases patients in Egypt. Int J Ophthalmol. 2014;7(5):891–897. - PMC - PubMed
    1. Ellenberg D, Azar DT, Hallak JA, Tobaigy F, Han KY, Jain S, Zhou Z, Chang JH. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res. 2010;29(3):208–248. - PMC - PubMed
    1. Shibuya M. VEGF-VEGFR signals in health and disease. Biomol Ther(Seoul) 2014;22(1):1–9. - PMC - PubMed
    1. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziche M, Bicknell R. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer. 2000;83(1):63–68. - PMC - PubMed
    1. Schlaeppi JM, Siemeister G, Weindel K, Schnell C, Wood J. Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor. J Cancer Res Clin Oncol. 1999;125(6):336–342. - PubMed

LinkOut - more resources